James F. White
Plus aucun poste en cours
Historique de carrière de James F. White
Anciens postes connus de James F. White
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - | - |
| COLUCID PHARMACEUTICALS INC | Fondateur | 01/01/2005 | - |
| President | 25/10/2006 | - | |
Hypnion, Inc.
 Hypnion, Inc. Miscellaneous Commercial ServicesCommercial Services Hypnion, Inc. discovered and developed neuroscience drugs. It focused on the development of novel therapeutics for the treatment of central nervous system disorders to serve the underserved markets of sleep and wake-alertness disorders and circadian rhythm abnormalities. The company was founded in 2000 and was headquartered in Lexington, MA. | Directeur des opérations | 29/07/2009 | - |
| Corporate Officer/Principal | 01/01/2001 | 29/07/2009 |
Formation de James F. White
| Purdue University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Chief Operating Officer | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Entreprise privées | 2 |
|---|---|
Hypnion, Inc.
Hypnion, Inc. Miscellaneous Commercial ServicesCommercial Services Hypnion, Inc. discovered and developed neuroscience drugs. It focused on the development of novel therapeutics for the treatment of central nervous system disorders to serve the underserved markets of sleep and wake-alertness disorders and circadian rhythm abnormalities. The company was founded in 2000 and was headquartered in Lexington, MA. | Commercial Services |
CoLucid Pharmaceuticals, Inc.
 CoLucid Pharmaceuticals, Inc. BiotechnologyHealth Technology CoLucid Pharmaceuticals, Inc. engaged in the development of therapeutics for neurological disorders. Its products included Lasmiditan, a neurally acting anti-migraine agent that is designed to delivered efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies and a Conjugated Stigmines platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. The company was founded by James F. White and Arthur M. Pappas in 2005 and was headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- James F. White
- Expérience
